After a median follow-up of about 10 years, the 114 patients who received ART had a 49% decreased risk of biochemical failure compared with the 159 patients who had the wait-and-see approach. The researchers observed only one grade 3 case of late toxicity in the ART group.
Previous studies also have shown the potential oncologic benefits of ART in this patient population. Yet, the use of ART for patients with pT3 prostate cancer following RP remains controversial.
Renal & Urology News would like to know the urologists’ view, so please answer the following poll question.